Latest news with #Surveillance
Time of India
4 days ago
- Politics
- Time of India
Ludhiana Deploys Surveillance Teams for Transparent By-Election
LUDHIANA: To ensure a fair and transparent Ludhiana West by-election, District Election Officer (DEO) Himanshu Jain directed Static Surveillance Teams (SSTs) and Flying Surveillance Teams (FSTs) to conduct thorough vehicle inspections to curb the illegal flow of liquor, cash, and contraband. Tired of too many ads? go ad free now According to a statement by the district administration, a total of 12 FSTs and nine SSTs are operating round-the-clock, conducting rigorous checks at 20 strategic locations within the Ludhiana West assembly segment. Additionally, eight Video Surveillance Teams (VSTs), one Video Viewing Team, and one Accounting Team have been formed to strengthen the expenditure monitoring mechanism. DEO Jain instructed these teams to intensify inspections at integrated checkpoints in collaboration with excise officials to prevent the illegal movement of liquor, cash, and other prohibited items. Jain clarified that carrying up to Rs 50,000 in cash requires no documentation. However, amounts between Rs 50,000 and Rs 10 lakh must be accompanied by valid proof, while cash exceeding Rs 10 lakh, even with documentation, will be reported to the for further scrutiny by the seizing teams. The DEO emphasised that all vehicles will be meticulously checked to prevent the circulation of illegal cash, liquor, contraband, or any materials intended to influence voters, ensuring a transparent electoral process.
Business Upturn
7 days ago
- Health
- Business Upturn
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
By GlobeNewswire Published on May 30, 2025, 01:30 IST FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30-June 3, 2025, in Chicago. This includes the latest findings from Castle's ongoing collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (NCI's SEER) Program Registries affirming the significant, independent risk stratification provided by DecisionDx-Melanoma in an expanded, real-world cohort of more than 13,500 patients who received the test as part of their melanoma care. 'Management decisions for melanoma patients, such as referrals for sentinel lymph node biopsy and surveillance intensity, are guided by a patient's risk of dying from their disease,' said Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. 'The findings being presented at ASCO demonstrate that the DecisionDx-Melanoma test can provide more precise mortality risk predictions based on a patient's unique tumor biology and can improve upon the population-based risk assessment provided by American Joint Committee on Cancer (AJCC) staging. This can, in turn, help clinicians tailor treatment approaches to individual patient needs.' Castle's presentations at ASCO will take place during the Melanoma/Skin Cancers poster session on Sunday, June 1, from 9 a.m. to 12 p.m. Central time in Hall A – Posters and Exhibits. Title: The 31-gene expression profile can guide better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: an NCI-SEER analysis Abstract: 9573 Poster Bd #: 56 Lead Author: Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio Study highlights : This study presents an updated validation of the DecisionDx-Melanoma test's ability to independently stratify CM patients' mortality risk within AJCC sub-stages (stages I-IIA, IIB-C and III) as part of Castle's ongoing collaboration with the NCI's SEER Program Registries. In this large, real-world cohort of 13,560 patients with CM – the largest real-world study of gene expression profile testing to date – the test provided significant risk stratification within the AJCC sub-groups (p<0.001). In multivariable analysis that included key AJCC staging criteria (i.e., Breslow thickness, ulceration and nodal status) and other commonly used clinicopathologic risk factors (e.g., age and mitotic rate), DecisionDx-Melanoma test results emerged as a significant predictor of melanoma-specific mortality (Class 2B hazard ratio=4.59, p<0.001; Class 1B/2A hazard ratio=3.42, p<0.001). Further, testing with DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients, providing further evidence of the test's association with improved patient survival and affirming the test's potential to inform risk-aligned treatment pathway decisions that may lead to improved patient outcomes. 1 : This study presents an updated validation of the DecisionDx-Melanoma test's ability to independently stratify CM patients' mortality risk within AJCC sub-stages (stages I-IIA, IIB-C and III) as part of Castle's ongoing collaboration with the NCI's SEER Program Registries. In this large, real-world cohort of 13,560 patients with CM – the largest real-world study of gene expression profile testing to date – the test provided significant risk stratification within the AJCC sub-groups (p<0.001). In multivariable analysis that included key AJCC staging criteria (i.e., Breslow thickness, ulceration and nodal status) and other commonly used clinicopathologic risk factors (e.g., age and mitotic rate), DecisionDx-Melanoma test results emerged as a significant predictor of melanoma-specific mortality (Class 2B hazard ratio=4.59, p<0.001; Class 1B/2A hazard ratio=3.42, p<0.001). Further, testing with DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients, providing further evidence of the test's association with improved patient survival and affirming the test's potential to inform risk-aligned treatment pathway decisions that may lead to improved patient outcomes. Title: Independent validation of a 16-protein test to assess malignant potential of small uveal melanocytic tumors Abstract: 9590 Poster Bd #: 73 Lead Author and Presenter: David Alan Reichstein, M.D., retina specialist and ocular oncologist at Tennessee Retina, Nashville, Tennessee Study highlights: UM is a rare but aggressive eye cancer with up to 50% of patients developing metastatic disease. While tumor biopsy-based molecular testing (i.e., DecisionDx-UM) is widely utilized to identify high-risk biology, repeated intraocular tumor biopsies are not feasible for monitoring small uveal melanocytic tumors of indeterminate malignant potential (UMTIMP). This multicenter study explored a novel diagnostic approach designed to analyze protein biomarkers in aqueous humor (AH) obtained through minimally invasive, in-office liquid biopsy of the anterior chamber of the eye. In the independent validation, the 17-biomarker test that evaluates 16 proteins and tumor diameter information successfully distinguished between low- and high-risk UM lesions with a sensitivity of 91%, specificity of 50%, negative predictive value of 92% and positive predictive value of 47%. If developed, this high-sensitivity test could help to accurately identify high-risk melanocytic lesions that would merit more invasive intraocular biopsy and further prognostic testing with DecisionDx-UM, -PRAME and -UM Seq . The study findings support a liquid biopsy approach to monitor suspicious UMTIMPs for malignant transformation to inform more timely decision-making and earlier therapeutic interventions to help improve patient outcomes. The full abstracts outlined above can be found at the ASCO website here. For more information regarding Castle's data at ASCO, please visit booth # 24149. About DecisionDx-Melanoma DecisionDx-Melanoma is a 31-gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient's individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma's clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test's results. Through March 31, 2025, DecisionDx-Melanoma has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma. About DecisionDx-UM DecisionDx-UM is Castle Biosciences' 15-gene expression profile (GEP) test that uses an individual patient's tumor biology to predict individual risk of metastasis in patients with uveal melanoma (UM). DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States. Since 2009, the American Joint Committee on Cancer (AJCC; v7 and v8) Staging Manual for UM has specifically identified the GEP test as a prognostic factor that is recommended for collection as a part of clinical care. Further, the National Comprehensive Cancer Network (NCCN) guidelines for UM include the DecisionDx-UM test result as a prognostic method for determining risk of metastasis and recommended differential surveillance regimens based on a Class 1A, 1B and 2 result. DecisionDx-UM is currently the only prognostic test for UM that has been validated in prospective, multi-center studies, and it has been shown to be a superior predictor of metastasis compared to other prognostic factors, such as chromosome 3 status, mutational status, AJCC stage and cell type. It is estimated that nearly 8 in 10 patients diagnosed with UM in the United States receive the DecisionDx-UM test as part of their diagnostic workup. About Castle Biosciences Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the significant, independent risk stratification provided by DecisionDx-Melanoma; DecisionDx-Melanoma's ability to (i) provide more precise mortality risk predictions and improve upon population-based risk assessment provide by AJCC staging, (ii) be a significant predictor of melanoma-specific mortality and (iii) improve patient survival and lead to improved patient outcomes; and DecisionDx-UM's ability to help accurately identify high-risk melanocytic lesions and improve patient outcomes. The words 'believe,' 'can' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report for the three months ended March 31, 2025 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law. Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. JCO Precis. Oncol . 2023; 7. doi: 10.1200/PO.23.00044 Investor Contact:Camilla Zuckero [email protected] Media Contact:Allison Marshall [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
CBS News
20-05-2025
- CBS News
Caught on video: Coral Gables woman says fake delivery man tried to break into her home
Woman says fake delivery man caught on video tried to break into her Coral Gables home Woman says fake delivery man caught on video tried to break into her Coral Gables home Woman says fake delivery man caught on video tried to break into her Coral Gables home A Coral Gables woman is warning others after a man posing as a pizza delivery driver allegedly trespassed on her property and tried to break into her home. The woman, who identified herself only as Melissa, shared surveillance video with CBS News Miami and is hoping someone will recognize the man. "He seemed to be making up a story on the spot," Melissa said. "He said something about being a pizza delivery man from DoorDash." Melissa said the man first appeared at her home just before 9 p.m. last Thursday. "I was home Thursday night and I heard sounds outside my home, so I activated my doorbell cameras and I asked the individual if I could help him with anything," she said. The man is heard on the video saying, "Yes, I have a pizza delivery for DoorDash." But Melissa said, "He didn't have anything in his hands to deliver, which I felt was odd. I told him he had the wrong place and I said I didn't order anything, and he said thank you and he walked away." Returned eight minutes later, walked into backyard Melissa said the man returned about eight minutes later and became more suspicious. "I noticed a hand reaching towards the glass and he walked up and he tried to peep in through the front door," she said. A dispatcher told her to lock her doors. Melissa said she then saw the man go past a "no trespassing" sign into her backyard. "At this point he is going into my backyard and past the no trespassing sign on my property and I am telling this to the operator. He was trespassing. At no point would a delivery man go into your backyard, especially after I told him I did not place any orders," she said. "I have not slept in my house since" "As I was speaking to the operator I could hear him jiggling my back door," Melissa said. "I have not slept in my house since Thursday night so I am hoping that someone out there can identify him. He has two tattoos on his arms and I could make out the letters, the cross letters of S and H and L and Y." Melissa also said, "I am not sure of this but I also think he may have tampered with my mail." She has since filed a police report. Coral Gables police told CBS News Miami they are investigating the case. Officers described the man as having a bald or shaved head, light-skinned, possibly Hispanic, and wearing a white shirt. Melissa said he was wearing an Adidas shirt. CBS News Miami has reached out to DoorDash for comment but has not yet received a response. It is not known if the man has targeted any other homes.
Yahoo
20-05-2025
- Business
- Yahoo
White House's Miran Dismisses Inflation Risk From Tariff Hikes
(Bloomberg) -- The White House's chief economist dismissed the idea that tariff increases will have a lasting impact on US inflation, and cited the potential for interest rates to get back down to pre-Covid levels. America, 'Nation of Porches' NJ Transit Train Engineers Strike, Disrupting Travel to NYC NJ Transit Makes Deal With Engineers, Ending Three-Day Strike 'Imports are only 14% of the economy — the ability of those types of things to move the needle on inflation are limited,' Stephen Miran, chair of the Council of Economic Advisers, said in an interview on Bloomberg Television's Surveillance. 'We have been introducing tariffs since day-one of this administration. And what we have seen is tariffs have started to come up' yet there's 'been no real meaningful effect on inflation.' Miran highlighted that the past three consumer price index releases all showed smaller increases than expected. The core gauge, which excludes food and inflation, was up 2.8% in April from the previous year, holding at the slowest pace since the breakout of inflation in the spring of 2021. Despite the moderation in price gains indicated by recent reports, Federal Reserve policymakers have held off on resuming interest-rate cuts. Officials have cited the potential for President Donald Trump's tariff increases to push up inflation. Chair Jerome Powell said earlier this month that while the effects 'could be short lived,' it's also possible the impact could be more persistent. Miran, who previously worked as a senior strategist at hedge fund Hudson Bay Capital, said that American importers 'have flexibility,' with the potential to make products domestically or buy them from 'other countries that treat us better.' That gives them leverage, he said. Volatility Possible 'In the short run, can there be volatility in prices and economic activity, just as there were in financial markets? Yeah, it can happen,' he said. 'But over time, we have the leverage — and that'll allow us to force the burden of the tariffs onto other countries.' As inflation pressures dating from the Biden administration's 'reckless' spending diminish, that will 'provide scope for interest rates to come down,' Miran said. 'We're going to bring interest rates down through expanding the supply side of the economy,' through policies including deregulation and Republican's tax package, Miran said. 'We get interest rates back to where they were pre-Covid, that's another point off the deficit,' he said, referring to the budget deficit to GDP ratio — which has run in excess of 6% in recent years. Rates remain well above pre-pandemic levels for now. Five-year Treasury yields are currently around 4.08%, compared with an average of 1.89% over the half-decade through 2019. --With assistance from Annmarie Hordern, Lisa Abramowicz and Jonathan Ferro. Why Apple Still Hasn't Cracked AI Anthropic Is Trying to Win the AI Race Without Losing Its Soul Microsoft's CEO on How AI Will Remake Every Company, Including His Cartoon Network's Last Gasp DeepSeek's 'Tech Madman' Founder Is Threatening US Dominance in AI Race ©2025 Bloomberg L.P.
Bloomberg
20-05-2025
- Business
- Bloomberg
White House's Miran Dismisses Inflation Risk From Tariff Hikes
The White House's chief economist dismissed the idea that tariff increases will have a lasting impact on US inflation, and cited the potential for interest rates to get back down to pre-Covid levels. 'Imports are only 14% of the economy — the ability of those types of things to move the needle on inflation are limited,' Stephen Miran, chair of the Council of Economic Advisers, said in an interview on Bloomberg Television's Surveillance. 'We have been introducing tariffs since day-one of this administration. And what we have seen is tariffs have started to come up' yet there's 'been no real meaningful effect on inflation.'
